StockData
Cue Biopharma, Inc. logo

Cue Biopharma, Inc. (CUE) stock

CUENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 8/30
$4.76+1.93 (+68.20%)

Close on Nov 18, 2026Market cap $34.58MP/E –Yield –

Cue Biopharma free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Cue Biopharma's free cash flow for the twelve months ending Jun 30, 2026 was -$50.17M. For fiscal 2025 it was -$21.86M. The highest annual figure on record is -$13.17M in fiscal 2017.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$21.86M–
FY2024Dec 31, 2024-$36.40M–
FY2023Dec 31, 2023-$39.96M–
FY2022Dec 31, 2022-$41.98M–
FY2021Dec 31, 2021-$39.75M–
FY2020Dec 31, 2020-$33.09M–
FY2019Dec 31, 2019-$30.84M–
FY2018Dec 31, 2018-$28.27M–
FY2017Dec 31, 2017-$13.17M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$29.00M–
Q1 FY2026Mar 31, 2026-$11.06M–
Q4 FY2025Dec 31, 2025-$1.08M–
Q3 FY2025Sep 30, 2025-$9.02M–
Q2 FY2025Jun 30, 2025-$3.44M–
Q1 FY2025Mar 31, 2025-$8.32M–
Q4 FY2024Dec 31, 2024-$9.03M–
Q3 FY2024Sep 30, 2024-$7.53M–
Q2 FY2024Jun 30, 2024-$10.00M–
Q1 FY2024Mar 31, 2024-$9.84M–
Q4 FY2023Dec 31, 2023-$10.96M–
Q3 FY2023Sep 30, 2023-$7.80M–
Q2 FY2023Jun 30, 2023-$10.37M–
Q1 FY2023Mar 31, 2023-$10.83M–
Q4 FY2022Dec 31, 2022-$10.52M–
Q3 FY2022Sep 30, 2022-$6.95M–
Q2 FY2022Jun 30, 2022-$12.91M–
Q1 FY2022Mar 31, 2022-$11.60M–
Q4 FY2021Dec 31, 2021-$10.65M–
Q3 FY2021Sep 30, 2021-$6.64M–
Q2 FY2021Jun 30, 2021-$10.02M–
Q1 FY2021Mar 31, 2021-$12.44M–
Q4 FY2020Dec 31, 2020-$7.11M–
Q3 FY2020Sep 30, 2020-$8.03M–
Q4 FY2019Dec 31, 2019-$6.45M–
Q3 FY2019Sep 30, 2019-$9.23M–
Q2 FY2019Jun 30, 2019-$6.68M–
Q1 FY2019Mar 31, 2019-$8.49M–
Q4 FY2018Dec 31, 2018-$4.02M–
Q3 FY2018Sep 30, 2018-$6.60M–
Q2 FY2018Jun 30, 2018-$7.22M–
Q1 FY2018Mar 31, 2018-$10.43M–
Q4 FY2017Dec 31, 2017-$1.86M–
Q3 FY2017Sep 30, 2017-$3.88M–
Q2 FY2017Jun 30, 2017-$3.40M–
Q1 FY2017Mar 31, 2017-$4.02M–

More Cue Biopharma figures

See a number that looks wrong?